JMP Securities Starts Aquestive Therapeutics (AQST) at Market Outperform

JMP Securities analyst Jason Butler initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Market Outperform rating and a price target of $29.00.

The analyst comments "The company's lead pipeline candidates address neurological diseases, where Aquestive is building commercial capabilities as it grows to become a fully integrated biopharma company. We believe FDA approvals for these wholly owned candidates are likely over the next 12-18 months, and drive the majority of our valuation for Aquestive, bolstered by manufacturing and royalty revenues from partnered programs. Our $29 price target is based on a probability-weighted NPV analysis of projected cash flows from Libervant (~$12.50/share), Sympazan (~$7/share), AQST-108 (~$5/share), APL-130277 (~$2/share), and Suboxone (~$2.50/share)."

For an analyst ratings summary and ratings history on Aquestive Therapeutics click here. For more ratings news on Aquestive Therapeutics click here.

Shares of Aquestive Therapeutics closed at $16.00 yesterday.

You May Also Be Interested In

• Lake Street Starts RF Industries Ltd. (RFIL) at Buy
• Morgan Stanley Starts Achieve Life Sciences (ACHV) at Overweight
• Freedom Broker Double Downgrades Mosaic (MOS) to Sell